PMID- 24771045
OWN - NLM
STAT- MEDLINE
DCOM- 20140925
LR  - 20171116
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 93
IP  - 9
DP  - 2014 Sep
TI  - KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence 
      of relapse after haploidentical transplantation using reduced intensity 
      conditioning and CD3/CD19-depleted grafts.
PG  - 1579-86
LID - 10.1007/s00277-014-2084-2 [doi]
AB  - Natural killer (NK)-cell alloreactivity after allogeneic hematopoietic cell 
      transplantation (HCT) is influenced by the interaction of killer-cell 
      immunoglobulin-like receptors (KIRs) on donor NK cells and human leukocyte 
      antigen (HLA) class I ligands on recipient cells. We investigated the influence 
      of donor KIR haplotype and KIR-ligand mismatch (MM) on relapse in 57 patients 
      with hematologic malignancies receiving haploidentical HCT after reduced 
      intensity conditioning and graft CD3/CD19 depletion. Of the 57 donors, 17 had KIR 
      haplotype A (29.8 %) and 40 had KIR haplotype B (70.2 %). A KIR-ligand MM was 
      found in 34 of 57 patients (59.6 %). There was no difference between donor KIR 
      haplotypes in non-relapse mortality (NRM, p = 0.200) but had a significantly 
      reduced incidence of relapse for patients with a haplotype B donor (p = 0.001). 
      In particular, patients in partial remission (PR) benefited more from a haplotype 
      B graft (p = 0.008) than patients in complete remission (CR, p = 0.297). 
      Evaluating KIR-ligand MM cumulative incidences of relapse (p = 0.680) or NRM 
      (p = 0.579), we found no significant difference. In conclusion, in the setting of 
      reduced intensity conditioning (RIC) and CD3/CD19-depleted haploidentical HCT, we 
      could not confirm the positive data with KIR-ligand MM but observed a significant 
      lower risk of relapse with a KIR haplotype B donor.
FAU - Michaelis, Sebastian U
AU  - Michaelis SU
AD  - Department of General Paediatrics, Haematology and Oncology, University 
      Children's Hospital, 72076, Tuebingen, Germany.
FAU - Mezger, Markus
AU  - Mezger M
FAU - Bornhauser, Martin
AU  - Bornhauser M
FAU - Trenschel, Rudolf
AU  - Trenschel R
FAU - Stuhler, Gernot
AU  - Stuhler G
FAU - Federmann, Birgit
AU  - Federmann B
FAU - Oevermann, Lena
AU  - Oevermann L
FAU - Kanz, Lothar
AU  - Kanz L
FAU - Handgretinger, Rupert
AU  - Handgretinger R
FAU - Bethge, Wolfgang A
AU  - Bethge WA
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140426
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - 0 (Antigens, CD19)
RN  - 0 (CD3 Complex)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Adult
MH  - Antigens, CD19/genetics/metabolism
MH  - Blood Group Incompatibility/complications/genetics
MH  - CD3 Complex/genetics/metabolism
MH  - Cell Separation
MH  - Female
MH  - Haplotypes
MH  - Hematologic Neoplasms/genetics/*surgery
MH  - Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Hematopoietic Stem Cells/*cytology/immunology/metabolism
MH  - Histocompatibility Antigens Class I/*genetics
MH  - Histocompatibility Testing
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Receptors, KIR/*genetics
MH  - Recurrence
MH  - Transplantation Conditioning/adverse effects/methods
MH  - Transplantation, Homologous
MH  - Young Adult
EDAT- 2014/04/29 06:00
MHDA- 2014/09/26 06:00
CRDT- 2014/04/29 06:00
PHST- 2013/09/17 00:00 [received]
PHST- 2014/04/08 00:00 [accepted]
PHST- 2014/04/29 06:00 [entrez]
PHST- 2014/04/29 06:00 [pubmed]
PHST- 2014/09/26 06:00 [medline]
AID - 10.1007/s00277-014-2084-2 [doi]
PST - ppublish
SO  - Ann Hematol. 2014 Sep;93(9):1579-86. doi: 10.1007/s00277-014-2084-2. Epub 2014 
      Apr 26.